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from outside the LabScientists aren’t the most likely models
to star in a calendar, but Sabrina Cohen,
a quadriplegic since a car accident at
14, believes they’re well deserving of the
honor. To raise money for her Sabrina
Cohen Foundation for Stem Cell Re-
search, she put together a ‘‘CELLebrity’’
calendar starring scientists in the field.
‘‘The work they’re doing gives people
like me a lot of hope, and it gives people
the will to do something to give back to
the cause,’’ Cohen says.
Advocates like Cohen are hard at work
raising awareness of the promise of
stem cell therapies, combating miscon-
ceptions about the field, fundraising to
support research, and pushing at both
the state and federal levels for the support
and freedom for scientists to advance
their work. Some make frequent appear-
ances on Capitol Hill, some recruit
celebrities to get behind the cause, and
others take their message to schools
and community groups.
Whatever their strategy, advocates say
scientists are crucial partners in educa-
tion and advocacy.
‘‘We need to present a united force to
convince and educate society,’’ says
Daniel Heumann, who was paralyzed in
a car accident shortly before he was dueSabrina Cohen with Drs. Josh Hare and Jeffrey Goldberg at the
CELLebrity calendar launch event. Photo courtesy of Charlotte
Libov.to begin college. Heumann,
a motivational speaker
whose hobbies include
wheelchair tennis and jump-
ing out of planes, helped
found Michigan Citizens for
Stem Cell Research & Cures
and sits on the Board of
Directors of the Christopher
& Dana Reeve Foundation.
‘‘To be an effective advo-
cate,’’ Heumann says, ‘‘you
need to be able to educate
people—they could be
regular people or legisla-
tors—on the issues you’re
passionate about.’’
‘‘We can’t entirely control
the negativity that’s going to
come with the area,’’ Cohen
adds. ‘‘The best I can do is
educate people properly.’’466 Cell Stem Cell 8, May 6, 2011 ª2011 ElsShe’s targeting schoolchildren, hoping
that students will take information home
to their parents, and that some might
grow up to do charity work.
Heumann has made it his mission to
‘‘stand up for’’ translational research,
and he’s particularly enthusiastic about
supporting young scientists via the Daniel
Heumann Young Scientists Fund of the
Christopher & Dana Reeve Foundation.
‘‘They are the ones who are going to find
the cure,’’ he says. ‘‘This is the future of
science, but I have to fight for the young
scientists to make sure they get the fund-
ing they need.’’ Heumann regards himself
as a venture capitalist, investing in prom-
ising researchers and helping them along
the way to big grants and groundbreaking
advances.
Don Reed, on the other hand, considers
himself the advocacy equivalent of a
middle linebacker—the position his son,
Roman, played until he broke his neck
on the football field. ‘‘I roam back and
forth and fight where I’m needed,’’ Don
Reed explains. ‘‘I call people and ask,
‘What’s happening? Tell me how I can
help you.’’’
‘‘I want every state in the nation to have
the freedom to do the research,’’ says
Reed, who is now monitoring the fightsevier Inc.in Minnesota, Oklahoma, and Florida,
among others. ‘‘We have to attack this
on a national level,’’ he adds, ‘‘with local
cooperation, for scientific freedom and
funding.’’
Reed, who believes ‘‘the private foun-
dation approach is limited—there’s not
enough money there,’’ helped pass Cali-
fornia’s Roman Reed Spinal Cord Injury
Research Act of 1999, which has provided
an average of $1.5 million in public
research funding per year. Several other
states have laws that add a surcharge to
traffic tickets to fund research—and
Reed is currently pushing for that method
of funding to be adopted by the California
legislature.
Marie Arturi is also pursuing a some-
what unusual fundraising strategy in order
to support stem cell research through the
Daniella Maria Arturi Foundation, which
she and her husband established after
losing their daughter to the rare blood
disorder Diamond Blackfan Anemia
(DBA). Inspired by that work, Arturi has
developed what she describes as a social
communications platform called buncee.
com. ‘‘My hope is that someone will love
it and buy it and I’ll be set up for funding.’’
Arturi’s foundation has already raised
several million dollars for DBA researchthrough more conventional
approaches, such as hosting
benefit events. She is also
particularly gratified to have
cultivated a growing commu-
nity of scientists working on
the disorder. ‘‘There are no
words to describe what
a miracle this little effort has
been,’’ says Arturi, who is
effusive in her praise and
appreciation for the scientists
in ‘‘the DBA family.’’
‘‘I couldn’t do what I do
without them,’’ she says. ‘‘I
want to say, ‘Thank you, thank
you, thank you.’’’
Arturi has also seen the
benefits for researchers.
Patient advocates can offer
bench scientists, in particular,
an encouraging reminder
Cell Stem Cell
Profileof the importance of their work—abroader
perspective that’s all too easily lost to the
inevitable myopia of research.
‘‘An important part of this is connecting
with what’s on the other side of the lab,’’
Arturi says. ‘‘Once researchers get that
exposure, I just see this amazing expo-
nential increase in dedication. It really
gets in their hearts.’’
Researchers, Reed says, can also
gain valuable insights from patients about
their conditions. He recalls a meeting
where scientists working on therapies for
spinal cord injury ‘‘got an education.
They thought the number-one concern
was walking, but they found out there
that it’s bowel and bladder control.
Some of them changed their focus after
that.’’
He urges scientists to invite a patient
advocate to meetings ‘‘to talk about
what they’re dealing with day in and day
out.’’
Arturi likes ‘‘a light touch’’ of advocacy
at scientific meetings. ‘‘We’re not killing
themwith, ‘You have to cure this disease.’
We’d love that, but we know it’s not
practical.’’People with spinal cord injuries and
other conditions that could benefit from
stem cell therapies are hopeful, Reed
adds, but not hopelessly naive. ‘‘There’s
a misconception that they’re ignorant
and willing to try anything,’’ but the advo-
cacy community is ‘‘educated and
informed,’’ he says. ‘‘Give us information,
tell us the risks, have us at the table.’’
‘‘Perhaps I won’t get up and walk,’’
Cohen remarks, ‘‘but maybe I’ll regain
the use of my hands.’’
Heumann, who’s been in a wheelchair
for 26 years, says, ‘‘Some sort of move-
ment or sensation would be the greatest
gift in the whole world.’’
He wants more scientists to join him on
the frontlines of advocacy. ‘‘We need to
be a united force to educate key deci-
sion-makers who really need to under-
stand what we’re trying to accomplish.
No one group—not scientists, not patient
advocates, not industry leaders—can do
it alone.’’ Scientists, Heumann says,
shouldn’t hide in the lab or behind their
PowerPoints. ‘‘We’re on the front lines
fighting for them, fighting for their work,’’
he adds, but many scientists ‘‘don’t doCell Stem Cwhat they need to do to allow us to under-
stand the science.’’
By sharing their work with nonscien-
tists—talking to media, to patients, to
policymakers—researchers can build
support for their efforts and help patients
make informed decisions, advocates
say. Cohen suggests that scientists
should not only pay attention to the work
of their peers, but also keep an eye on
the miracle cures and breakthrough treat-
ments being peddled by quacks around
the world.
‘‘They also need to know what threats
are coming, what threats could kill their
research,’’ Reed says. ‘‘If the educated
don’t take part, the ignorant will be all
too glad to make the decisions. There
are a few scientists who will stand up
and fight’’—scientists helped California’s
embryonic stem cell funding initiative
succeed in 2004, Reed points out—‘‘but
not enough.’’
‘‘Anytime I meet a scientist,’’ Reed
says, ‘‘I try to find out what they’re
doing and what help they need—and I
also ask them what they’re doing for the
cause.’’Anna C. Davison
Santa Barbara, CA, USA
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